Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
2,900 HKD | -0,34% | +1,75% | -9,38% |
Voorlopige winst- en verliesrekening: Sino Biopharmaceutical Limited
Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Omzet 1 | 24.234 | 23.647 | 26.861 | 28.780 | 26.199 | 29.403 | 32.435 | 35.916 |
Variatie | - | -2,42% | 13,59% | 7,14% | -8,97% | 12,23% | 10,31% | 10,73% |
EBITDA 1 | 6.399 | 5.753 | 5.174 | 6.908 | 6.476 | 7.947 | 8.499 | 9.367 |
Variatie | - | -10,09% | -10,07% | 33,52% | -6,26% | 22,71% | 6,95% | 10,21% |
Bedrijfsresultaat (EBIT) 1 | 4.840 | 4.098 | 4.182 | 5.861 | 5.439 | 6.499 | 7.185 | 8.123 |
Variatie | - | -15,32% | 2,03% | 40,17% | -7,2% | 19,49% | 10,54% | 13,07% |
Betaalde rente 1 | -230 | -323,4 | -308,6 | -439,1 | -495,2 | -352,4 | -362,3 | -343,9 |
Resultaat voor belastingen (EBT) 1 | 5.584 | 5.013 | 18.573 | 5.779 | 5.215 | 6.981 | 7.429 | 8.395 |
Variatie | - | -10,22% | 270,49% | -68,89% | -9,76% | 33,86% | 6,41% | 13,01% |
Nettowinst (verlies) 1 | 2.707 | 2.771 | 14.608 | 2.544 | 2.332 | 3.417 | 3.191 | 3.636 |
Variatie | - | 2,38% | 427,17% | -82,59% | -8,32% | 46,53% | -6,6% | 13,95% |
Datum van publicatie | 30-03-20 | 23-03-21 | 31-03-22 | 31-03-23 | 28-03-24 | - | - | - |
Balansprognose: Sino Biopharmaceutical Limited
Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Nettoschuld 1 | - | -1.266 | -3.107 | -1.915 | 2.742 | -3.049 | -7.652 | -12.269 |
Variatie | - | - | -345,42% | -161,64% | 43,19% | -211,2% | -350,97% | -260,34% |
Datum van publicatie | 30-03-20 | 23-03-21 | 31-03-22 | 31-03-23 | 28-03-24 | - | - | - |
Verwachte kasstroom: Sino Biopharmaceutical Limited
Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
CAPEX 1 | 2.141 | 1.582 | 1.561 | 1.760 | 2.643 | 1.450 | 1.456 | 1.427 |
Variatie | - | -26,09% | -1,33% | 12,73% | 50,17% | -45,15% | 0,41% | -1,96% |
Vrije kasstroom (FCF) 1 | 3.184 | 3.743 | 3.805 | 4.505 | 3.423 | 4.478 | 5.950 | 5.714 |
Variatie | - | 17,56% | 1,66% | 18,4% | -24,03% | 30,84% | 32,85% | -3,95% |
Datum van publicatie | 30-03-20 | 23-03-21 | 31-03-22 | 31-03-23 | 28-03-24 | - | - | - |
Verwachte financiële ratio's: Sino Biopharmaceutical Limited
Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Winstgevendheid | ||||||||
EBITDA-marge (%) | 26,4% | 24,33% | 19,26% | 24% | 24,72% | 27,03% | 26,2% | 26,08% |
EBIT-marge (%) | 19,97% | 17,33% | 15,57% | 20,37% | 20,76% | 22,1% | 22,15% | 22,62% |
EBT-marge (%) | 23,04% | 21,2% | 69,14% | 20,08% | 19,9% | 23,74% | 22,9% | 23,37% |
Nettomarge (%) | 11,17% | 11,72% | 54,38% | 8,84% | 8,9% | 11,62% | 9,84% | 10,12% |
FCF-marge (%) | 13,14% | 15,83% | 14,17% | 15,65% | 13,06% | 15,23% | 18,34% | 15,91% |
Vrije kasstroom/nettoresultaat (%) | 117,63% | 135,08% | 26,05% | 177,12% | 146,78% | 131,06% | 186,43% | 157,14% |
Winstgevendheid | ||||||||
ROA | 5,01% | 6,54% | 27,11% | 4,08% | 3,65% | 5,46% | 5,22% | 5,6% |
ROE | 8,97% | 17,49% | 62,11% | 8,47% | 7,74% | 10,15% | 9,32% | 9,83% |
Financiële gezondheid | ||||||||
Hefboom (schuld/ebitda) | - | - | - | - | 0,42x | - | - | - |
Schuld/vrije kasstroom | - | - | - | - | 0,8x | - | - | - |
Kapitaalintensiteit | ||||||||
Kapitaaluitgaven/omzet (%) | 8,83% | 6,69% | 5,81% | 6,12% | 10,09% | 4,93% | 4,49% | 3,97% |
CAPEX / EBITDA (%) | 33,45% | 27,5% | 30,17% | 25,48% | 40,81% | 18,24% | 17,13% | 15,24% |
CAPEX / FCF (%) | 67,24% | 42,27% | 41,03% | 39,06% | 77,21% | 32,37% | 24,47% | 24,97% |
Bestanddelen per aandeel | ||||||||
Kasstroom per aandeel 1 | 0,2831 | 0,2833 | 0,2859 | 0,3294 | 0,3274 | 0,3713 | 0,4003 | 0,4384 |
Variatie | - | 0,08% | 0,92% | 15,22% | -0,61% | 13,4% | 7,82% | 9,51% |
Dividend per aandeel 1 | 0,0488 | 0,0671 | 0,0648 | 0,105 | 0,0462 | 0,0623 | 0,0736 | 0,0825 |
Variatie | - | 37,46% | -3,52% | 62,15% | -55,96% | 34,7% | 18,17% | 12,09% |
Nettoactief per aandeel 1 | 1,648 | 0,89 | 1,614 | 1,611 | 1,621 | 1,849 | 1,967 | 2,089 |
Variatie | - | -45,98% | 81,34% | -0,2% | 0,63% | 14,06% | 6,4% | 6,19% |
WPA 1 | 0,1439 | 0,1474 | 0,7326 | 0,1215 | 0,1259 | 0,181 | 0,1698 | 0,1926 |
Variatie | - | 2,45% | 397,01% | -83,42% | 3,62% | 43,73% | -6,19% | 13,46% |
Aantal aandelen (in duizend) | 18.810.956 | 18.789.999 | 18.756.114 | 18.481.249 | 18.399.239 | 18.183.969 | 18.183.969 | 18.183.969 |
Datum van publicatie | 30-03-20 | 23-03-21 | 31-03-22 | 31-03-23 | 28-03-24 | - | - | - |
2024 * | 2025 * | |
---|---|---|
K/w-verhouding | 15,1x | 16,1x |
PBR-ratio | 1,48x | 1,39x |
EV/omzet | 1,59x | 1,3x |
Dividendrendement | 2,27% | 2,69% |
WPA & Dividend
Historische koers/winstverhouding
Evolutie van de historische prestaties
Kwartaalomzet - Afwijkingspercentage
- Beurs
- Aandelen
- Koers 1177
- Financiën Sino Biopharmaceutical Limited